SAN DIEGO, May 2, 2017 /PRNewswire/ -- OncoSec Medical
Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing
DNA-based intratumoral cancer immunotherapies, announced today that
Robert H. Pierce, MD, OncoSec Chief
Scientific Strategist, will speak at the Biomarkers &
Immuno-Oncology World Congress, taking place May 2-4, 2017, in Philadelphia, PA.
Details of the presentation are as follows:
Title: In
situ Vaccination: Potential Mechanism(s) of Action and
Biomarker Development
Session title: Personalized
Cancer Vaccines
Date and Time: Tuesday, May 2, 2017 at 1:35 PM EST
Location: Philadelphia
Marriott Downtown
Topics to be addressed are as follows:
- Intratumoral therapies that aim to enhance tumor
immunogenicity, offer the potential to generate tumor
antigen-specific TIL and augment anti-PD1 blockade;
- Clinical development of multiple in situ vaccinations:
including TLR agonists, STING agonists, oncolytic viruses and
proinflammatory cytokines;
- Potential safety advantages of in situ vaccinations; and
- Mechanism of action-based biomarker development.
For more information about the Biomarkers & Immuno-Oncology
World Congress 2017, please visit
http://www.biomarkerworldcongress.com/.
About OncoSec Medical Incorporated
OncoSec is a
biotechnology company developing DNA-based intratumoral
immunotherapies with an investigational technology,
ImmunoPulse®, for the treatment of cancer.
ImmunoPulse® is designed to enhance the local delivery
and uptake of DNA-based immune-targeting agents, such as IL-12. In
Phase I and II clinical trials, ImmunoPulse® IL-12 has
demonstrated a favorable safety profile and evidence of anti-tumor
activity in the treatment of various solid tumors as well as a
systemic clinical and immune response. OncoSec's lead program,
ImmunoPulse® IL-12, is currently in clinical development
for metastatic melanoma and triple-negative breast cancer. The
program's current focus is on the significant unmet medical need in
patients with melanoma who are refractory or non-responsive to
anti-PD-1/PD-L1 therapies. In addition to ImmunoPulse®
IL-12, the Company is also identifying and developing new
immune-targeting agents for use with the ImmunoPulse®
platform. For more information, please visit www.oncosec.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by words such as
"can," "may," "will," "suggest," "look forward to," "potential,"
"understand," and similar references to future periods.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based on
management's current preliminary expectations and are subject to
risks and uncertainties, which may cause our results to differ
materially and adversely from the statements contained herein.
Potential risks and uncertainties that could cause actual results
to differ from those predicted include, among others, the
following: uncertainties inherent in pre-clinical studies and
clinical trials, such as the ability to enroll patients in clinical
trials and the risk of adverse events; unexpected new data, safety
and technical issues; our ability to raise additional funding
necessary to fund continued operations; and the other factors
discussed in OncoSec's filings with the Securities and Exchange
Commission.
Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
disclaims any obligation to update any forward-looking statements
to reflect new information, events or circumstances after the date
they are made, or to reflect the occurrence of unanticipated
events.
CONTACT:
Investor Relations:
OncoSec Medical Incorporated
855-662-6732
investors@oncosec.com
Media Relations:
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oncosec-to-present-at-biomarkers--immuno-oncology-world-congress-2017-300449530.html
SOURCE OncoSec Medical Incorporated